Licensed providers prescribe semaglutide through a simple online evaluation. Skip the office visit and retail pharmacy markup. Treatment starts at $297 per month.
How to Get Semaglutide Prescribed Online — Without the $1,000+ Price Tag: telehealth enables access to FDA-approved GLP-1 medications without in-person visits. Clinical trials show 15-22% weight loss. Weight Method connects patients with licensed providers for virtual consultations starting at $297/month with direct-to-door shipping.
Key Fact
Semaglutide prescriptions exceeded 9 million in the U.S. in 2024, with telehealth platforms accounting for a growing share. The STEP trials demonstrated 14.9% average body weight loss over 68 weeks, making semaglutide the most-prescribed GLP-1 for weight management.
Source: IQVIA Prescription Data (2024); STEP 1 Trial (NEJM, 2021)
Complete an online health assessment, receive provider review within 24 hours, and get semaglutide shipped to your home starting at $297/mo — a fraction of the $1,350/mo retail price.
Semaglutide — the active ingredient in Wegovy and Ozempic — is the most widely prescribed GLP-1 medication for weight loss. In the STEP clinical trials, patients lost an average of 14.9% of their body weight over 68 weeks. Getting this medication no longer requires an in-person visit to a specialist. Licensed telehealth providers can evaluate you and prescribe semaglutide through a secure online consultation.
The online prescription process is straightforward. You complete a health assessment that covers your weight, height, medical history, current medications, and health goals. A licensed physician or nurse practitioner reviews your information, determines whether semaglutide is clinically appropriate, and selects your starting dose. If approved, your medication is prepared by a licensed pharmacy and shipped directly to your home.
At Weight Method, semaglutide subscriptions start at $297 per month. This is a fraction of the retail price — Wegovy lists at approximately $1,350 per month, and Ozempic at around $900-1,000 per month at retail pharmacies. Our pricing includes the medication, the medical evaluation, ongoing provider supervision, and monthly home delivery.
Adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition, who are 18 or older and have no contraindications like medullary thyroid carcinoma history.
The FDA approved semaglutide (Wegovy) for chronic weight management in adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related condition. These conditions include type 2 diabetes, hypertension, high cholesterol, obstructive sleep apnea, and cardiovascular disease. At Weight Method, our providers follow these established criteria when evaluating patients.
Semaglutide is particularly well-suited for patients who have tried diet and exercise without achieving lasting results. Clinical trials consistently show that semaglutide produces significantly more weight loss than lifestyle modification alone. The STEP 1 trial compared semaglutide 2.4 mg to placebo — both groups received diet and exercise counseling — and the semaglutide group lost nearly six times more weight.
There are important contraindications. Semaglutide should not be used by individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN 2). It is not recommended during pregnancy or breastfeeding. Patients with a history of pancreatitis should discuss risks with their provider. These are the same screening criteria used by in-person providers — the evaluation is equally thorough whether conducted online or in a clinic.
Semaglutide starts at 0.25 mg weekly and increases monthly through 0.5 mg, 1.0 mg, 1.7 mg to the 2.4 mg maintenance dose, with your provider managing each escalation.
Semaglutide follows a standard dose escalation schedule designed to minimize gastrointestinal side effects. Treatment begins at 0.25 mg per week for the first four weeks. This is a sub-therapeutic dose intended to let your body acclimate to the medication. The dose then increases monthly: 0.5 mg, 1.0 mg, 1.7 mg, and finally the maintenance dose of 2.4 mg weekly.
Your online provider manages this escalation based on your individual response. If you experience significant nausea or other GI side effects at a particular dose, your provider may slow the escalation — staying at a lower dose for additional weeks before increasing. This personalized approach is a hallmark of quality telehealth care and a reason why ongoing provider access matters more than just the initial prescription.
Most patients begin noticing appetite reduction within the first two weeks, even at the starting dose. Clinically meaningful weight loss — typically defined as 5% or more of body weight — usually occurs within the first three months. Maximum weight loss is generally achieved between 12 and 18 months of continuous treatment. At Weight Method, your provider tracks your progress and adjusts your plan throughout the treatment journey.
Online semaglutide at $297/mo is roughly 78% less than retail Wegovy at $1,350/mo, with the same active ingredient and an integrated prescription-to-delivery experience.
The primary difference between getting semaglutide through an online provider like Weight Method and walking into a retail pharmacy is cost. Brand-name Wegovy costs approximately $1,350 per month at retail without insurance. Even with insurance, many patients face prior authorization hurdles, step therapy requirements, and significant copays. Some insurance plans do not cover weight loss medications at all.
Online providers that work with compounding pharmacies can offer semaglutide at dramatically lower prices. At Weight Method, semaglutide is $297 per month — roughly 78% less than the retail price of Wegovy. Compounded semaglutide contains the same active ingredient and is prepared by licensed, regulated pharmacies. The FDA permits compounding of medications to address individual patient needs and improve access.
Beyond cost, the online model simplifies the entire process. There is no need to schedule an in-person appointment, obtain a paper prescription, and then fight with the pharmacy over insurance approvals. With Weight Method, the medical evaluation, prescribing, and pharmacy fulfillment are integrated into a single seamless experience. Your medication arrives at your door each month without you having to manage any of the logistics.
Expect reduced appetite and food cravings within 7-14 days, manageable GI side effects during dose escalation, and steady weight loss of 1-2% of body weight per month.
The first few weeks on semaglutide bring noticeable changes. Most patients report a significant reduction in appetite and food cravings within 7-14 days of their first injection. The concept of "food noise" — the persistent mental preoccupation with eating — tends to quiet considerably. Many patients describe this as the most transformative aspect of the medication.
Side effects during the initial weeks are common but typically manageable. The most frequently reported side effects are nausea, constipation, diarrhea, and mild abdominal discomfort. These tend to be most pronounced during dose increases and generally improve as your body adjusts. Eating smaller meals, staying hydrated, and avoiding high-fat foods can help minimize GI symptoms. Your Weight Method provider is available to help manage any side effects you experience.
Over the following months, you can expect steady, progressive weight loss. In clinical trials, patients on semaglutide 2.4 mg lost an average of about 1-2% of their body weight per month during the active weight loss phase. For a 250-pound person, that translates to roughly 2.5-5 pounds per month. While individual results vary, the trajectory is consistently downward when combined with moderate lifestyle modifications. Your provider monitors your progress and ensures your treatment remains on track.
Take our 2-minute quiz to see if you qualify for GLP-1 treatment.
Start QuizFree consultation. No commitment.